LLY vs PTGX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
PTGX exhibits a strong deterministic health profile with a Piotroski F-Score of 7/9 and a fortress-like balance sheet (Current Ratio 12.71, Debt/Equity 0.02). However, the company is in a speculative pre-commercial phase, evidenced by a staggering Price/Sales ratio of 146.96 and negative profit margins. While analysts maintain a 'strong_buy' based on the late-stage pipeline (Icotyde and Rusfertide), significant insider selling by the CEO and CFO creates a divergence between institutional optimism and internal sentiment.
Compare Another Pair
Related Comparisons
LLY vs PTGX: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Protagonist Therapeutics, Inc. (PTGX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.